Impact of cerebral malaria on brain distribution of mefloquine

Drug Metabolism Letters

Volumn 3, Issue 1, 2009, Pages 15-17

  de Lagerie, Sylvie Barraud ^a,c   Fernandez, Christine ^a,c   German Fattal, Michèle ^b   Gantier, Jean Charles ^a   Gimenez, François ^a   Farinotti, Robert ^a,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS UMR8162 Surgical Center M Lannelongue   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Blood brain barrier; Cerebral malaria; Efflux; Mefloquine; P glycoprotein; Transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MEFLOQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MALARIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; INFLAMMATION; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE;

ANIMALS; ANTIMALARIALS; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERYTHROCYTES; FEMALE; MALARIA, CEREBRAL; MEFLOQUINE; MICE; MICE, INBRED C57BL; P-GLYCOPROTEIN; PLASMODIUM BERGHEI;

MUS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 66149158227     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209787176407     Document Type: Article

References (18)

1. World Health Organization (WHO). 55th World Health Assembly. Global Fund to Fight AIDS, Tuberculosis and Malaria. WHO document no. A55/INF.DOC./ 6. Available at: http://www.who.int
2. Chanthavanich, T.; Looareesuwan, S.; White, N.J.; Warrell, D.A.; Warrell, M.J.; Di Giovanni, J.H.; von Bredow, J. Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. Am. J. Trop. Med. Hyg., 1985, 34, 1028.
3. Rendi-Wagner, P.; Noedl, H.; Wernsdorfer, W.H.; Wiedermann, G.; Mikolasek, A.; Kollaritsch, H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop., 2002, 81, 167.
4. Ronn, A.M.; Ronne-Rasmussen, J.; Gotzsche, P.C.; Bygbjerg, I. C. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop. Med. Int. Health, 1998, 3, 83.
5. van Riemsdijk, M.M.; Sturkenboom, M.C.; Pepplinkhuizen, L.; Stricker, B.H. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J. Clin. Psychiatry, 2005, 66, 199.
6. Warner, J. Adverse events associated with mefloquine. Advice to warn patients about rare side effects overturns accepted practice. BMJ, 1996, 313, 1554.
7. Weinke, T.; Trautmann, M.; Held, T.; Weber, G.; Eichenlaub, D.; Fleischer, K.; Kern, W.; Pohle, H. D. Neuropsychiatric side effects after the use of mefloquine. Am. J. Trop. Med. Hyg., 1991, 45, 86.
8. Schlagenhauf, P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J. Travel Med., 1999, 6, 122.
9. Dow, G.S.; Koenig, M.L.; Wolf, L.; Gerena, L.; Lopez-Sanchez, M.; Hudson, T.H.; Bhattacharjee, A.J. The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains. Antimicrob. Agents Chemother., 2004, 48, 2624.
10. Allen, J.D.; Brinkhuis, R.F.; Wijnholds, J.; Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 1999, 59, 4237.
11. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 1998, 95, 15665.
12. Sun, H.; Dai, H.; Shaik, N.; Elmquist, W. F. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev., 2003, 55, 83.
13. Barraud de Lagerie, S.; Comets, E.; Gautrand, C.; Fernandez, C.; Auchere, D.; Singlas, E.; Mentre, F; Gimenez, F. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br. J. Pharmaco, 2004, 141, 1214.
14. Fernandez, C.; Buyse, M.; German-Fattal, M.; Gimenez, F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci., 2004, 7, 359.
15. Ho, E.A.; Piquette-Miller, M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets, 2006, 6, 295.
16. Kampfl, A.; Pfausler, B.; Haring, H. P. Denchev, D.; Donnemiller, E; Schmutzhard, E. Impaired microcirculation and tissue oxygenation in human cerebral malaria: a single photon emission computed tomography and near-infrared spectroscopy study Am. J. Trop. Med. Hyg., 1997, 56, 585.
17. Penet, M.F.; Viola, A.; Confort-Gouny, S.; Le Fur, Y.; Duhamel, G.; Kober, F.; Ibarrola, D.; Izquierdo, M.; Coltel, N.; Gharib, B.; Grau, G.E.; Cozzone, P. J. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J. Neurosci., 2005, 25, 7352.
18. Kennan, R.P.; Machado, F.S.; Lee, S.C.; Desruisseaux, M.S.; Wittner, M.; Tsuji, M.; Tanowitz, H. B. Reduced cerebral blood flow and N-acetyl aspartate in a murine model of cerebral malaria. Parasitol. Res., 2005, 96, 302.